Background. Two years ago in this Journal, Neuhaus et al .
type oligosaccharide (9) . The hepatic-medimed clearance of rl-PA from plasma is quite rapid, with an initial plasma half-time previously reported to be -4 min (t0) . The rapid clearance of n-PA from plasma by the liver appears to be mediated by two mechanisms: I) a specific uptake system on hepatic parenchymal cells, and 2) a mannose-specific uptake system on hepatic endothelial and Kupffer cells (11) . However, despite the short plasma half-life of rt-PA, there is evidence that fibrinolytic activity continues for hours after the administration of the drug, presumably because of its activity at the thrombus (12) and the release into the circulation of rt-PA initially bound to the endothelial surface (13) .
In the present stud ; on kinetics of the front-loaded accelerated regimen, plasma rt-PA antigen concentration reached a maximum of 4 tag/ml after the bolus injection and plasma levels >3 ag/ml were maintained daring the lot 30 min . These latter values are approximately 30% to 50% higher than the plasma rt-PA levels obtained with the standard dosage regimen (14, 15) . In comparison, single bolus injections of rt-PA resulted in mean peak rt-PA Concentrations that are even higher (9 .8 ng/ml) (16) . These values of circulating rt-PA are 30 to 100 times higher than the plasma levels of plasminogen activator inhibitor-I (PAI-1) in plasma . Levels of this magnitude should further diminish or even render negligible any attenuating effects of PAW on rt-PA activity (17) and may contribute to ttte improved patency rates reported with front-loaded accelerated infusions .
The derived pharmacukinetic variables for the frontloat!ed accelerated regimen of rt-PA are nearly identical with previously published values for the standard regimen (9), indicating that the hepatic rt-PA clearance mechanism or mechanisms have the capacity to deal with the elevated plasma levels that accompany the front-loaded regimen . Despite the increased plasma levels of rt-PA produced by the front-loaded regimen, the systemic effects of the enzyme, as measured by decrements in circulating levels of fibrinogen, plasminogen and alpha 2-antiplasmin, are similar to those obtained with the standard dosage regimen (14) . This finding confirms that rt-PA is a fibrin-specific agent and a relatively inefficient activator of circulating plasminogen (17) .
Implications. The present study (8), together with the earlier article (1) describing the improved efficacy of a front-loaded accelerated regimen of rt-PA, indicates that the pharmacokinetic properties of rt-PA can be expected to yield an agent with nearly optimal lhrombulytic properties for both the achievement of maximal early patency rates and limited systemic plasminogen activation and fibrinogen breakdown . One can reasonably argue that the front-loaded accelerated regimen should supplant the standard regimen in patients who are designated to receive rl-PA . However, it remains to be seen if the accelerated regimen, which appears to exploit some of the most desirable properties of rt-PA on a theoretic basis (18), will have any additional impact on survival . The ongoing GUSTO and Thrombolysis in Myocardial Infarction (TIMI-4) trials, which are designed to 0735-109719265 .00 accelerated n-PA = recombinant dss¢-type plasmloogea amrva,or e cwCtpare the front-loaded accelerated rt-PA regimen with the standard streptokinase and APSAC regimens and with the combination of two thrombolytc agents, should be very informative in clarifying the desirable properties of an optimal thrombolytic regimen .
Thrombolytk therapy of acute myocardial infarction has now been under inleasise investigation for a decade . Its immediate goal is to reestablish patency efthe infarct-related artery as rapidly as possible and to maintain its patency without causing serious bleeding. Although the effectiveness of this mode of therapy in reducing mortality has been well established {19), there is no consensus regarding the optimal thrmboiytic agent, much less the optimal dose or the scheme of administration . There is evidence that n-PA is more effective than streptokinase in early opening of oc . eluded coronary arteries (5), especially when administered in a front-beaded, accelerated regimen but reocclusion remains a problem . Whether this improved pharmacologic action can be translated into improved patient survival is still unresolved. Although reocchminn can be reduced by prolonged infusie-s of ri-PA (20, 21) , the increased time appears to be assoeialCd with an increased risk of serious bleeding (22).
The future. An important goal in improving the care of patients with acute myocardial infarction during the next decade will be to optimize thrombolytic therapy . It is possible that a "one-two punch" consisting of a frost-loaded accelerated regimen of rt-PA, such as that developed by Neuhaus et al . (1) and Studied by Tanswell et al . (8) , followed by the infusion or injection of a more slowly acting, nonfibrin-specific agent to help sustain patency, as is being tested in TIM(-4 with anistreplase and in GUSTO with streptokiaise, will prove to be advantageous . The incidence of serious bleeding, the principal risk of thrombolytic therapy, appears to be dose dependent, at least insofar as n-PA is concerned (5,6) and is related, albeit in a complex fashion, to baseline risk factors such as age, hypertension, gender ad perhaps body size . The potential benefit of thrombolytic therapy varies even more widely than the risk and is a complex function of baseline left ventricular fashion, the size and location of the jeopardized myocardium and the time interval between the onset of symptoms and treatment. Optimal thrombolytic therapy will probably not be identical for all patients but will require a judicious balance between risk and benefit . Thus, the optimal dose of one or more thrombolytic agents is likely to be lower in a small (40 kg) 80-ymr-old woman with borderline hypertension and evi-VAUGHAN AND 5uaeNwALo EDITORIAL COMMENT 1077 deuce of a modest-size inferior-wall infarct who is seen 4 6 after the onset of chest pain (relatively high risk"iow potential benelill than in a younger (45year old), 100-kg man without a history of hyperteosion who is seen I b after the onset of a large anterior wall infarct (relatively low rislalhigh potential benefit) . When the dust settles . there will probably not he a single standard thrombolytic regimen (such as 100 mg of rt-PA for 3 h . 1 .5 mU of streptokinase for I h or a 30-mg bolus of anistreplase) for all patients with evolving myocardial infarction but rather a regimen that is tailored to the individual patient. Therefore. detailed pharmacokinetic studies, such as those presented by Tanswell et al . (8) , may contribute importantly to optimizing thrombolytic therapy .
